highly significantp = .009
45% [95% CI, 34–59] in non‐CR patients, p = .051) and a highly significant improvement of 5‐year OS ( p = .009), but not of lung‐RFS ( p = .3).
45% [95% CI, 34–59] in non‐CR patients, p = .051) and a highly significant improvement of 5‐year OS ( p = .009), but not of lung‐RFS ( p = .3).